IOP-lowering effect lasting for 24 hours of Tapcom combination ophthalmic solution switched from Tapros ophthalmic solution 0.0015% and Timoptol XE Ophthalmic Solution 0.5%.
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Tafluprost/timolol (Primary)
- Indications Open-angle glaucoma
- Focus Therapeutic Use
- 16 Feb 2017 Status changed from recruiting to discontinued.
- 01 Sep 2015 New trial record